Seattle Genetics Rises On CEO's Appearance On CNBC (SGEN)

Shares of Seattle Genetics

have surged during Tuesday's trading session after the company's CEO appeared on CNBC earlier in the day. The stock has gained 4.24% to $16.49 on heavy volume. More than 2.53 million SGEN shares have already changed hands compared to a daily average of less than 1 million. Seattle Genetics, Inc. (Seattle Genetics) is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.